COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Protocol No
ADCT-402-311-DLBCL
Principal Investigator
Mehdi Hamadani
Phase
III
Summary
This study will be conducted in two parts. Part 1 of the study will test if the investigational drug, called loncastuximab tesirine in combination with rituximab, is a safe and effective treatment for DLBCL. Part 2 will compare the combination of loncastuximab tesirine with rituximab (Lonca-R) to a standard treatment regimen for DLBCL: rituximab plus gemcitabine and oxaliplatin (R-GemOx). The purpose of Part 2 is to evaluate whether Lonca-R is more effective than R-GemOx in decreasing the growth and spread of lymphoma, preventing it from coming back quickly and helping patients live longer.
Description
Loncastuximab Tesirine with Rituximab vs Immunochemotherapy in DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL